ALZHEIMER'S RESEARCH UK

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  —

  Not reported

• Cash

  +55.8%

  £2,290,395 → £3,567,297

• Net assets

  +15.4%

  £30,746,590 → £35,486,248

• Employees

  +10.2%

  244 → 269

• Operating profit

  -44.7%

  £8,573,040 → £4,739,658

• Wages

  +11.4%

  £10,192,885 → £11,349,864

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. ALZHEIMER'S RESEARCH UK 2010-07-30 → present
2. ALZHEIMER'S RESEARCH TRUST 1998-12-10 → 2010-07-30

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

Grant Thornton UK LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The Trustees are confident that the Group is a going concern, and that there are triggers and safeguards which can be deployed to ensure the future operation of the Group, if needed.”

Group structure

1. ALZHEIMER'S RESEARCH UK · parent
   1. Alzheimer's Research Trading Limited 100% · UK · to sell gifts and merchandise through an online shop and to Gift Aid any profits directly to the Charity.
   2. Alzheimer's Brain Bank UK 50% · UK · to protect and promote the health of the public, in particular by establishing, promoting and maintaining banks of brain tissue for research into the cause, prevention, treatment and cure of Alzheimer's disease and associate neurodegenerative diseases and disorders.

Significant events

• “In 2024/25, the charity raised over £60 million for the first time in its history from supporters, with 250,000 people supporting them, including 86,000 monthly donors.”
• “The first-ever Alzheimer's drugs were licensed in the UK, but their rejection for use on the NHS leaves thousands without access to potentially life-changing treatments.”
• “In 2024/25, research funded by Alzheimer's Research UK resulted in more than 530 scientific publications.”
• “Two new modifiable risk factors for dementia (uncorrected vision loss and high cholesterol) were reported by The Lancet, bringing the total to 14.”
• “Regional fundraising efforts in 2024/25 raised an impressive £3.9m, a 28% increase on the prior year.”
• “The Omaze partnership raised an extraordinary £3.9m through the Scotland House Draw, contributing to a total of £8m raised by Omaze to end the heartbreak of dementia.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

4

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.